H. Tiddens (Rotterdam, The Netherlands), N. Hoiby (Copenhagen, Denmark)
Respiratory viral agents in cystic fibrosis
J. A. Kastelik, A. Hale, D. G. Peckham, C. Etherington, I. Clifton, S. Conway (Leeds, United Kingdom)
|   |
Achromobacter (A.) xylosoxidans in cystic fibrosis: prevalence and clinical relevance
F. De Baets, S. Van Daele, P. Schelstraete, F. Haerynck, M. Vaneechoutte (Ghent, Belgium)
| |
Possible mechanisms of action of azithromycin in cystic fibrosis
C. Cigana, E. Nicolis, B. M. Assael, P. Melotti (Verona, Italy)
| |
Bronchiectasis score on computed tomography (CT) is more sensitive than forced expiratory volume in one second (FEV1) in children and adults with cystic fibrosis (CF)
P. A. de Jong, A. Lindblad, L. Rubin, W. C. Hop, J. C. de Jongste, M. Brink, H. A. Tiddens (Rotterdam, Netherlands; Gothenburg, Sweden)
| |
Modelling the cancer risk potentially associated with repetitive CT scanning in cystic fibrosis
P. A. de Jong, K. Golmohammadi, Y. Nakano, J. R. Mayo, M. H. Lequin, H. A. Tiddens, J. Aldrich, P. D. Paré, D. D. Sin (Rotterdam, Netherlands; Edmonton, Vancouver, Canada)
| |
Characterization of cystic fibrosis airway epithelium in vitro
S. M. Stick, A. Kicic, E. N. Sutanto, A. Fonceca, D. A. Knight (Perth, Nedlands, Australia; British Columbia, Canada)
| |
New proteomic biomarkers of cystic fibrosis: a comparison with non-CF bronchiectasis
R. D. Gray, M. Imrie, G. MacGregor, M. Dewar, A. C. Boyd, J. A. Innes, D. Porteous, A. P. Greening (Edinburgh, United Kingdom)
| |
Effect of inhaled L-arginine on airway nitric oxide in cystic fibrosis patients
H. Grasemann, F. Kurtz, F. Ratjen (Essen, Germany; Toronto, Canada)
| |